{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:33:50Z","timestamp":1768318430427,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Chiesi GmbH, Germany"},{"name":"Universit\u00e4tsklinikum M\u00fcnster"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40259-024-00690-1","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T08:51:19Z","timestamp":1732956679000},"page":"153-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8409-2886","authenticated-orcid":false,"given":"Malte","family":"Lenders","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise Raphaela","family":"Menke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rudnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Cybulla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Brand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"issue":"9647","key":"690_CR1","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1016\/S0140-6736(08)61589-5","volume":"372","author":"YA Zarate","year":"2008","unstructured":"Zarate YA, Hopkin RJ. Fabry\u2019s disease. Lancet. 2008;372(9647):1427\u201335.","journal-title":"Lancet"},{"issue":"21","key":"690_CR2","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743\u20139.","journal-title":"JAMA"},{"issue":"1","key":"690_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease. N Engl J Med. 2001;345(1):9\u201316.","journal-title":"N Engl J Med"},{"issue":"4","key":"690_CR4","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CEM, Donker-Koopman WE, et al. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004;66(4):1589\u201395.","journal-title":"Kidney Int"},{"issue":"1","key":"690_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, et al. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27(1):256\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"690_CR6","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neu\u00dfer LP, Rudnicki M, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. J Am Soc Nephrol. 2018;29:2879\u201389.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"690_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","volume":"126","author":"SJ van der Veen","year":"2019","unstructured":"van der Veen SJ, van Kuilenburg ABP, Hollak CEM, et al. Antibodies against recombinant alpha-galactosidase A in Fabry disease: subclass analysis and impact on response to treatment. Mol Genet Metab. 2019;126(2):162\u20138.","journal-title":"Mol Genet Metab"},{"issue":"17","key":"690_CR8","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1007\/s40265-021-01621-y","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Mechanisms of neutralizing anti-drug antibody formation and clinical relevance on therapeutic efficacy of enzyme replacement therapies in Fabry disease. Drugs. 2021;81(17):1969\u201381.","journal-title":"Drugs"},{"key":"690_CR9","unstructured":"Replagal\u00ae (agalsidase alfa). Replagal\u00ae (agalsidase alfa) ed. Dublin: Takeda Pharmaceuticals; 2022."},{"key":"690_CR10","unstructured":"FABRAZYME\u00ae (Agalsidase beta) for injection, for intravenous use. FABRAZYME\u00ae (Agalsidase beta) for injection, for intravenous use ed. Cambridge, USA Genzyme Corporation; 2021."},{"issue":"5","key":"690_CR11","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1021\/acs.bioconjchem.8b00133","volume":"29","author":"I Ruderfer","year":"2018","unstructured":"Ruderfer I, Shulman A, Kizhner T, et al. Development and analytical characterization of pegunigalsidase alfa, a chemically cross-linked plant recombinant human \u03b1-galactosidase-a for treatment of Fabry disease. Bioconjug Chem. 2018;29(5):1630\u20139.","journal-title":"Bioconjug Chem"},{"issue":"3","key":"690_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/jimd.12080","volume":"42","author":"R Schiffmann","year":"2019","unstructured":"Schiffmann R, Goker-Alpan O, Holida M, et al. Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: a 1-year Phase 1\/2 clinical trial. J Inherit Metab Dis. 2019;42(3):534\u201344.","journal-title":"J Inherit Metab Dis"},{"key":"690_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.omtm.2022.07.009","volume":"26","author":"M Lenders","year":"2022","unstructured":"Lenders M, Pollmann S, Terlinden M, et al. Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase alfa. Mol Ther Methods Clin Dev. 2022;26:323\u201330.","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"6","key":"690_CR14","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jmg-2023-109445","volume":"61","author":"EL Wallace","year":"2024","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet. 2024;61(6):520\u201330.","journal-title":"J Med Genet"},{"issue":"6","key":"690_CR15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/jmg-2023-109818","volume":"61","author":"M Lenders","year":"2024","unstructured":"Lenders M, Brand E. Comment to: head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study-determination of immunogenicity. J Med Genet. 2024;61(6):531\u20133.","journal-title":"J Med Genet"},{"issue":"6","key":"690_CR16","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","volume":"141","author":"M Lenders","year":"2018","unstructured":"Lenders M, Schmitz B, Brand SM, et al. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion. J Allergy Clin Immunol. 2018;141(6):2289-92.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"690_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/joim.12647","volume":"282","author":"M Lenders","year":"2017","unstructured":"Lenders M, Oder D, Nowak A, et al. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med. 2017;282(3):241\u201353.","journal-title":"J Intern Med"},{"issue":"5","key":"690_CR18","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.3390\/ijms22052680","volume":"22","author":"M Lenders","year":"2021","unstructured":"Lenders M, Scharnetzki D, Heidari A, et al. Generation and characterization of a polyclonal human reference antibody to measure anti-drug antibody titers in patients with Fabry disease. Int J Mol Sci. 2021;22(5):2680.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"690_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/jimd.12176","volume":"43","author":"F Stappers","year":"2020","unstructured":"Stappers F, Scharnetzki D, Schmitz B, et al. Neutralising anti-drug antibodies in Fabry disease can inhibit endothelial enzyme uptake and activity. J Inherit Metab Dis. 2020;43(2):334\u201347.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"690_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ymgme.2014.08.002","volume":"114","author":"T Kizhner","year":"2015","unstructured":"Kizhner T, Azulay Y, Hainrichson M, et al. Characterization of a chemically modified plant cell culture expressed human \u03b1-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015;114(2):259\u201367.","journal-title":"Mol Genet Metab"},{"key":"690_CR21","doi-asserted-by":"publisher","first-page":"1395287","DOI":"10.3389\/fgene.2024.1395287","volume":"15","author":"DP Germain","year":"2024","unstructured":"Germain DP, Linhart A. Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease. Front Genet. 2024;15:1395287.","journal-title":"Front Genet"},{"issue":"5","key":"690_CR22","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/GIM.0b013e318170f868","volume":"10","author":"D Bodensteiner","year":"2008","unstructured":"Bodensteiner D, Scott CR, Sims KB, et al. Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme. Genet Med. 2008;10(5):353\u20138.","journal-title":"Genet Med"},{"issue":"8","key":"690_CR23","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/nbt.1484","volume":"26","author":"J Wang","year":"2008","unstructured":"Wang J, Lozier J, Johnson G, et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol. 2008;26(8):901\u20138.","journal-title":"Nat Biotechnol"},{"key":"690_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12795","author":"M Holida","year":"2024","unstructured":"Holida M, Linhart A, Pisani A, et al. A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. J Inherit Metab Dis. 2024. https:\/\/doi.org\/10.1002\/jimd.12795.","journal-title":"J Inherit Metab Dis"},{"key":"690_CR25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3389\/fimmu.2016.00021","volume":"7","author":"M Krishna","year":"2016","unstructured":"Krishna M, Nadler SG. Immunogenicity to biotherapeutics\u2014the role of anti-drug immune complexes. Front Immunol. 2016;7:21.","journal-title":"Front Immunol"},{"issue":"4","key":"690_CR26","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1542\/peds.2003-0988-L","volume":"114","author":"TE Hunley","year":"2004","unstructured":"Hunley TE, Corzo D, Dudek M, et al. Nephrotic syndrome complicating alpha-glucosidase replacement therapy for Pompe disease. Pediatrics. 2004;114(4):e532\u20135.","journal-title":"Pediatrics"},{"issue":"4","key":"690_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1681\/ASN.2013030290","volume":"25","author":"H Debiec","year":"2014","unstructured":"Debiec H, Valayannopoulos V, Boyer O, et al. Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy. J Am Soc Nephrol. 2014;25(4):675\u201380.","journal-title":"J Am Soc Nephrol"},{"issue":"9981","key":"690_CR28","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/S0140-6736(15)60731-0","volume":"385","author":"P Ronco","year":"2015","unstructured":"Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient\u2019s care. Lancet. 2015;385(9981):1983\u201392.","journal-title":"Lancet"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00690-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00690-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00690-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T21:24:30Z","timestamp":1737494670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00690-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["690"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00690-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]},"assertion":[{"value":"4 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open Access funding enabled and organized by Projekt DEAL.\u00a0This study received funding from Chiesi GmbH, Germany (investigator initiated non-interventional studies: DJUS21002971, DJUS13008931, DJUS13011311). The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of the article, or the decision to submit it for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"ML received research\/travel grants and\/or speaker honoraria from Amicus Therapeutics, Sanofi, Chiesi, Sumitomo Pharma, and Takeda. EB received research grants and\/or speaker honoraria from Amicus Therapeutics, Sanofi, Chiesi, Takeda, and Eleva. MR received speaker honoraria, congress support, and research grants from Sanofi, Chiesi, and Amicus Therapeutics. MC received speaker honoraria\/travel grants from Takeda, Amicus Therapeutics, Idorsia, and Alexion. ERM has nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The original contributions presented in the study are included in the article and Online Resources; further inquiries can be directed to the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"All investigations were performed after approval by the Medical Association of Westphalian-Lippe and the Ethics Committee of the Medical Faculty of the University of Muenster (project no. 2011-347-f, date of report: 7 July 2011) and in accordance with the Declaration of Helsinki.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all included patients for analysis and publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors have contributed to the article by participating in the conception and design (ML), acquisition of data (ML, ERM, MR, MC, EB) or formal analysis (ML, ERM) and interpretation of data (ML, EB), drafting the article (ML, EB) or revising it critically for important intellectual content (ERM, MR, MC). All authors read and approved the final version of the manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution"}}]}}